TRCT
CADL icon

Tower Research Capital (TRC)’s Candel Therapeutics CADL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.4K Buy
4,408
+1,427
+48% +$10.8K ﹤0.01% 2824
2026
Q1 		$14.6K Buy
2,981
+1,102
+59% +$6K ﹤0.01% 3695
2025
Q4 		$10.6K Sell
1,879
-3,753
-67% -$20.2K ﹤0.01% 3735
2025
Q3 		$28.7K Sell
5,632
-3,976
-41% -$23K ﹤0.01% 2977
2025
Q2 		$48.6K Buy
9,608
+7,527
+362% +$38.7K ﹤0.01% 2993
2025
Q1 		$11.8K Buy
2,081
+624
+43% +$5.1K ﹤0.01% 3508
2024
Q4 		$12.6K Sell
1,457
-1,279
-47% -$7.56K ﹤0.01% 3598
2024
Q3 		$19K Buy
2,736
+1,484
+119% +$9.22K ﹤0.01% 3268
2024
Q2 		$7.76K Sell
1,252
-2,450
-66% -$18.4K ﹤0.01% 4428
2024
Q1 		$5.85K Sell
3,702
-3,031
-45% -$4.5K ﹤0.01% 4478
2023
Q4 		$9.9K Sell
6,733
-1,914
-22% -$1.86K ﹤0.01% 4331
2023
Q3 		$7.96K Buy
8,647
+385
+5% +$445 ﹤0.01% 4416
2023
Q2 		$10.4K Buy
8,262
+1,686
+26% +$2.49K ﹤0.01% 4126
2023
Q1 		$9K Sell
6,576
-638
-9% -$1.24K ﹤0.01% 4469
2022
Q4 		$13K Buy
7,214
+3,077
+74% +$6.09K ﹤0.01% 3582
2022
Q3 		$13K Buy
4,137
+2,918
+239% +$9.89K ﹤0.01% 4259
2022
Q2 		$4K Buy
1,219
+1,165
+2,157% +$4.67K ﹤0.01% 5175
2022
Q1 		$0 Buy
+54
New +$268 ﹤0.01% 6112

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC)'s CADL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Candel Therapeutics (CADL) stake by 48% in Q2 2026, buying an estimated $10.8K and bringing the position to 4,408 shares worth $45.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2824.

Tower Research Capital (TRC) first reported a position in CADL in Q1 2022 and has held it in 18 quarters since. The position peaked at $48.6K in Q2 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Tower Research Capital (TRC) held 4,408 shares of Candel Therapeutics worth $45.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,427 Candel Therapeutics shares in Q2 2026, an estimated $10.8K.
  • Candel Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2824 holding.
  • Tower Research Capital (TRC) first reported a position in Candel Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Candel Therapeutics position peaked at $48.6K in Q2 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.